SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase

Journal of Medicinal Chemistry

Volumn 49, Issue 3, 2006, Pages 1034-1046

  Powers, Jay P ^a   Piper, Derek E ^a   Li, Yang ^a   Mayorga, Veronica ^a   Anzola, John ^a,c   Chen, James M ^a,b   Jaen, Juan C ^a   Lee, Gary ^a   Liu, Jinqian ^a   Peterson, M Greg ^a   Tonn, George R ^a   Ye, Qiuping ^a   Walker, Nigel P C ^a   Wang, Zhulun ^a  

^a AMGEN INC   (United States)

^b GILEAD SCIENCES   (United States)

^c Kalypsys Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (3,4 DICHLOROBENZYLIDENE) 3 (2 FLUOROBENZENESULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (3,4 DICHLOROBENZYLIDENE) 3 (2 THIOPHENESULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (3,4 DICHLOROBENZYLIDENE) 3 (3 METHOXYBENZENESULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (3,4 DICHLOROBENZYLIDENE) 3 (4 CHLOROBENZENESULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (3,4 DICHLOROBENZYLIDENE) 3 (4 FLUOROBENZENESULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (3,4 DICHLOROBENZYLIDENE) 3 (4 METHOXYBENZENESULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (3,4 DICHLOROBENZYLIDENE) 3 (4 METHYLBENZENESULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (3,4 DICHLOROBENZYLIDENE) 3 (BENZENESULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (3,4 DICHLOROBENZYLIDENE) 3 (BUTYLSULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (3,4 DICHLOROBENZYLIDENE) 3 (METHANESULFONYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 CHLOROBENZYLIDENE) 3 (BENZOYLAMINO) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 CHLOROBENZYLIDENE) 3 AMINO 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 CHLOROBENZYLIDENE) 3 BENZYL 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 CHLOROBENZYLIDENE) 3 ETHYL 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 CHLOROBENZYLIDENE) 3 METHYL 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 CHLOROBENZYLIDENE) 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 CYANOBENZYLIDENE) 3 AMINO 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 DIMETHYLAMINOBENZYLIDENE) 3 AMINO 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 FLUOROBENZYLIDENE) 3 AMINO 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 METHOXYBENZYLIDENE) 3 AMINO 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 METHYLBENZYLIDENE) 3 AMINO 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 NITROBENZYLIDENE) 3 AMINO 4 OXO 2 THIONOTHIAZOLIDINE; 5 (4 NITROBENZYLIDENE) 3 METHYL 4 OXO 2 THIONOTHIAZOLIDINE; 5 (BENZYLIDENE) 3 AMINO 4 OXO 2 THIONOTHIAZOLIDINE; ENZYME INHIBITOR; NONNUCLEOSIDE RNA POLYMERASE INHIBITOR; PEGINTERFERON ALPHA2A; RIBAVIRIN; RNA POLYMERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HEPATITIS C VIRUS; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC SITE; AVIAN MYELOBLASTOSIS VIRUS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DIARRHEA VIRUSES, BOVINE VIRAL; DNA-DIRECTED RNA POLYMERASES; MODELS, MOLECULAR; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIONES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 32344433896     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050859x     Document Type: Article

References (64)

1. Choo, Q.-L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA Clone Derived from a Blood-Bourne Non-A, Non-B Viral Hepatitis Genome. Science 1989, 244, 359-362.
2. Kuo, G.; Choo, Q.-L.; Alter, H. J.; Gitnick, G. L.; Redeker, A. G.; Purcell, R. H.; Miyamura, T.; Dienstag, J. L.; Alter, M. J.; Stevens, C. E.; Tegtmeir, G. E.; Bonino, F.; Colombo, M.; Lee, W.-S.; Kuo, C.; Berger, K.; Shuster, J. R.; Overby, L. R.; Bradley, D. W.; Houghton, M. An Assay for Circulating Antibodies to a Major Etiologic Virus of Non-A, Non-B Hepatitis. Science 1989, 244, 362-364.
3. Hoofnagle, J. H. Hepatitis C: The Clinical Spectrum of Disease. Hepatology 1997, 26, 15S-20S.
4. Monto, A.; Wright, T. L. The Epidemiology and Prevention of Hepatocellular Carcinoma. Semin. Oncol. 2001, 28, 441-449.
5. Di Bisceglie, A. M. Hepatitis C and Hepatocellular Carcinoma. Hepatology 1997, 26, 34S-38S
6. McHutchison, J. G.; Gordon, S. C.; Schiff, E. R.; Shiffman, M. L.; Lee, W. M.; Rustgi, V. K.; Goodman, Z. D.; Ling, M.-H.; Cort, S.; Albrecht, J. K. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C. N. Engl. J. Med. 1998, 339, 1485-1492.
7. Zeuzem, S.; Feinman, S. V.; Rasenack, J.; Heathcote, E. J.; Lai, M.-Y.; Gane, E.; O'Grady, J.; Reichen, J.; Diago, M.; Lin, A.; Hoffman, J.; Brunda, M. J. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C. N. Engl. J. Med. 2000, 343, 1666-1672.
8. Lauer, G. M.; Walker, B. D. Hepatitis C Virus Infection. N. Engl. J. Med. 2001, 545, 41-52.
9. Perni, R. B.; Kwong, A. D. Inhibitors of Hepatitis C Virus NS3-4A Protease: An Overdue Line of Therapy. In Progress in Medicinal Chemistry; King, F. D., Oxford, A. W., Eds.; Elsevier Science: New York, 2002; Volume 39, pp 215-255.
10. Kadow, J. F.; Scola, P. M. Antiviral Agents. In Annual Reports in Medicinal Chemistry; Doherty, A. M., Ed.; Academic Press: San Francisco, 2002; Volume 37, pp 133-147.
11. Wang, W.; Preville, P.; Morin, N.; Mounir, S.; Cai, W.; Siddiqui, M. A. Hepatitus C Viral IRES Inhibition by Phenazine and Phenazine-like Molecules. Bioorg. Med. Chem. Lett. 2000, 10, 1151-1154
12. Witherell, G. W. ISIS-14803, Isis Pharmaceuticals. Curr. Opin. Invest. Drugs. 2001, 2, 1523-1529.
13. Jaen, J. C.; Piper, D. E.; Powers, J. P.; Walker, N. P.; Li, Y. NS5b HCV Polymerase Inhibitors. PCT Int. Appl. WO-0177091, 2001.
14. Altamura, S.; Tomei, L.; Koch, U.; Neuner, P. J. S.; Summa, V. Diketoacid Derivitives as Inhibitors of Polymerases. PCT Int. Appl. WO-00006529, 2000.
15. Gardelli, C.; Ciuliano, C.; Harperr, S.; Koch, U.; Narjes, F.; Ontoria, U.; Jesus, M.; Poma, M.; Ponz, S.; Stansfield, I.; Summa, V. Preparation of 2-Aryldihydroxypyrimidine-4-carboxylic Acids as Hepatitis C Viral Polymerrase Inhibitors. PCT Int. Appl. WO-0206246, 2002.
16. Bailey, T. R.; Young, D. C. Methods for Treating or Preventing Viral Infections and Associated Diseases. PCT Int. Appl. WO-00013708, 2000.
17. Bailey, T. R.; Young, D. C. Compounds, Compositions and Methods for Treating or Preventing Viral infections and Associated Diseases. PCT Int. Appl. WO-00010573, 2000.
18. Young, D. C.; Bailey, T. R. Methods for Treating or Preventing Viral Infections and Associated Disease. PCT Int. Appl. WO-00018231, 2000.
19. Hashimoto, H.; Mizutani, K.; Yoshida, A. Preparation of Heterocyclic Compounds as Remedies for Hepatitis C. PCT Int. Appl. WO-0147883, 2001.
20. Baginski, S. G.; Pevear, D. C.; Seipel, M.; Sun, S. C. C.; Benetatos, C. A.; Chunduru, S. K.; Rice, C. M.; Collet, M. S. Mechanism of Action of a Pestivirus Antiviral Compound. Proc. Nat. Acad. Sci. 2000, 97, 7981-7986.
21. A preliminary account of this work has been described: Powers, J. P.; Anzola, J.; Chen, J.; Jaen, J. C.; Li, Y.; Lee, G.; McNally, J.; Mayorga, V.; Peterson, M. G.; Piper, D.; Walker, N.; Wang, Z. SAR and Mechanism of Novel HCV NS5b RNA Polymerase Inhibitors. Presented at the 5th Annual Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, Jan 26-31, 2003.
22. Chan, L.; Reddy, T. J.; Proulx, M.; Das, S. K.; Pereira, O.; Wang, W.; Siddiqui, A.; Yannopoulos, C. G.; Poisson, C.; Turcotte, N.; Drouin, A.; Alaoui-Ismaili, M. H.; Bethell, R. Hamel, M.; L'Heureux, L.; Bilimoria, D. Nguyen-Ba, N. Identification of N,N-Disubstituted Phenylalanines as a Novel Class of Inhibitors of Hepatitis C NS5B Polymerase. J. Med. Chem. 2003, 46, 1283-1285.
23. Dhanak, D.; Duffy, K. J.; Johnston, V. K.; Lin-Goerke, J.; Darcy, M.; Shaw, A. N.; Gu, B.; Silverman, C.; Gates, A. T.; Nonnemacher, M. R.; Earnshaw, D. L.; Casper, D. J.; Kaura, A.; Baker, A.; Greenwood, C.; Gutshall, L. L.; Maley, D.; DelVecchio, A.; Macarron, R.; Hofmann, G. A.; Alnoah, Z.; Cheng, H.-Y.; Chan, G.; Khandekar, S.; Keenan, R. M.; Sarisky, R. T. Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase. J. Biol. Chem. 2002, 277, 38322-38327.
24. Wang, M.; Ng, K. K._S.; Cherney, M. M.; Chan, L.; Yannopoulos, C. G.; Bedard, J.; Morin, N.; Nguyen-Ba, N.; Alaoui-Ismaili, M. H.; Bethell, R. C.; James, M. N. G. Non-Nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5b Polymerase. J. Biol. Chem. 2003, 278, 9489-9495.
25. Beaulieu, P. L.; Bos, M.; Bousquest, Y.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; LaPlante, S.; Poupart, M.-A.; Lefebvre, S.; McKercher, G.; Pellerin, C.; Austel, V.; Kukolj, G. Non-Nucleoside Inhibitors of the Hepatitis C Virus NS5B Polymerase: Discovery and Preliminary SAR of Benzamidazole Derivitives. Bioorg. Med. Chem. Lett. 2004, 14, 119-124.
26. Chan, L.; Das, S. K.; Reddy, T. J.; Poisson, C.; Proulx, M.; Pereira, O.; Courchesne, M.; Roy, C.; Wang, W.; Siddqui, A.; Yannopoulos, C. G.; Nguyen-Ba, N.; Labrecque, D.; Bethell, R.; Hamel, M.; Courtmanche-Asselin, P.; L'Heureux, L.; David, M.; Nicolas, O.; Brunette, S.; Bilimoria, D.; Bedard, J. Discovery of Thiophene-2-carboxylic Acids as Potent Inhibitors of HCV NS5B Polymerase and HCV Subgenomic RNA Replication. Part 1: Sulfonamides. Bioorg. Med. Chem. Lett. 2004, 14, 793-796.
27. Chan, L.; Pereira, O.; Reddy, T. J.; Das, S. K.; Poisson, C.; Courchesne, M.; Proulx, M.; Siddiqui, A.; Yannopoulos, C. G.; Nguyen-Ba, N.; Roy, C.; Nasturica, D.; Moinet, C.; Bethell, R.; Hamel, M.; L'Heureux, L.; David, M.; Nicolas, O.; Courtmanche-Asselin, P.; Brunette, S.; Bilimoria, D.; Bedard, J. Discovery of Thiophene-2-carboxylic Acids as Potent Inhibitors of HCV NS5B Polymerase and HCV subgenomic RNA Replication. Part 2: Tertiary Amides. Bioorg. Med. Chem. Lett. 2004, 14, 797-800.
28. Pace, P.; Nizi, E.; Pacini, B.; Pesci, S.; Matassa, V.; De Francesco, R.; Altamura, S.; Summa, V. The Monomethyl Ester of Meconic Acid is an Active Site Inhibitor of HCV NS5B RNA-Dependent RNA Polymerase. Bioorg. Med. Chem. Lett. 2004, 14, 3257-3261.
29. Summa, V.; Petrocchi, A.; Pace, P.; Matessa, V. G.; De Francesco, R.; Altamura, S.; Tomei, L.; Koch, U.; Neuner, P. Discovery of α,γ- Diketo Acids as Potent Selective Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA Polymerase. J. Med. Chem. 2004, 47, 14-17.
30. Summa, V.; Petrocchi, A.; Matassa, V. G.; Taliani, M.; Laufer, R.; De Francesco, R.; Altamura, S.; Pace, P. HCV NS5b RNA-Dependent RNA Polymerase Inhibitors: From α,γ-Diketoacids to 4,5-Dihydroxypyrimidine- or 3-Methyl-5-hydroxypyrimidinonecarboxylic acids. Design and Synthesis. J Med. Chem. 2004, 47, 5336-5339.
31. Ships, G. W., Jr.; Deng, Y.; Wang, T.; Popovici-Muller, J.; Curran, P. J.; Rosner, K. E.; Cooper, A. B.; Griijavallabhan, V.; Butkiewicz, N.; Cable, M. Aminothiazole Inhibitors of HCV RNA Polymerase. Bioorg. Med. Chem. Lett. 2005, 15, 115-119.
32. Beaulieu, P. L.; Bousquet, Y.; Gauthier, J.; Gillard, J.; Marquis, M.; McKercher, G.; Pellerin, C.; Valois, S.; Kukolj, G. Non-Nucleoside Benzimidazole-Based Allosteric Inhibitors of the Hepatitis C Virus NS5B Polymerase: Inhibition of Subgenomic Hepatitis C Virus RNA Replicons in Huh-7 Cells. J. Med. Chem. 2004, 47, 6884-6892.
33. Harper, S.; Pacini, B.; Avolio, S.; Di Filippo, M.; Migliaccio, G.; Laufer, R.; De Francesco, R.; Rowley, M.; Narjes, F. Development and Preliminary Optimization of Indole-N-Acetamide Inhibitors of Hepatitis C Virus NS5B Polymerase. J. Med. Chem. 2005, 48, 1314-1317.
34. Gordon, C. P.; Keller, P. A. Control of Hepatitis C: A Medicinal Chemistry Perspective. J. Med. Chem. 2005, 48, 1-20.
35. Wu, J. Z.; Hong, Z. Targeting NS5B RNA-Dependent RNA Polymerase for Anti-HCV Chemotherapy. Curr. Drug Targets-Infectious Disorders 2003, 3, 207-219.
36. Behrens, S.-E.; Tomei, L.; De Francesco, R. Identification and Properties of the RNA-Dependent RNA Polymerase of Hepatitis C Virus. EMBO J. 1996, 15, 12-22.
37. De Francesco, R.; Behrens, S.-V.; Tomei, L.; Altamura, S.; Jiricny, J. RNA-Dependent RNA Polymerase of Hepatitis C Virus. Methods Enzymol. 1996, 275, 58-67.
38. Yuan, Z.-H.; Kumar, U.; Thomas, H. C.; Wen, Y.-M.; Monjardino, J. Expression, Purification, and Partial Characterization of HCV RNA Polymerase. Biochem. Biophys. Res. Commun. 1997, 232, 231-235.
39. Ago, H.; Adachi, T.; Yoshida, A.; Yamamoto, M.; Habuka, N.; Yatsunami, K.; Miyano, M. Crystal Structure of the RNA-Dependent RNA polymerase of Hepatitis C virus. Structure (London) 1999, 7, 1417-1426.
40. Lesburg, C. A.; Cable, M. B.; Ferrari, E.; Hong, Z.; Mannarino, A. F.; Weber, P. C. Crystal Structure of the RNA-Dependent RNA polymerase from Hepatitis C Virus Reveals a Fully Encircled Active Site. Nat. Struct. Biol. 1999, 6, 937-943.
41. Bressanelli, S.; Tomei, L.; Roussel, A.; Incitti, I.; Vitale, R. L.; Mathieu, M.; De Francesco, R.; Rey, F. A. Crystal Structure of the RNA-Dependent RNA Polymerase of Hepatitis C Virus. Proc. Natl. Acad. Sci. 1999, 96, 13034-13039.
42. Tomei, L.; Vitale, R. L.; Incitti, I.; Serafini, S.; Altamura, S.; Vitelli, A.; De Francesco, R. Biochemical Characterization of a Hepatitis C Virus RNA-Dependent RNA polymerase lacking the C-Terminal Hydrophobic Sequence. J. Gen. Virol. 2000, 81, 759-767. Unless otherwise noted in the body of the text further references to the HCV NS5b should be taken to be describing the Δ21 variant. Assays and Structural information were obtained with Δ21 NS5b with a C-terminal 10-His tag.
43. Hanefeld, W.; Schlitzer, M. Synthesis of 3-Aminorhodanine Derivatives as Aldose Reductase Inhibitors. J. Heterocycl. Chem. 1995, 32, 1019-1025.
44. El-Bindary, A. A.; Ghoneim, M. M.; El-Sonbati, A. Z.; Barakat, S. A. Thermodynamics of Substituted Rhodanine III: Potentiometric and Spectrophotometric Studies of Complexes of Some Transition Metals with 3-Phenylsulfonamidorhodanine. Monatsh. Chem. 1998, 129, 1250-1265.
45. Topliss, J. G. A Manual Method for Applying the Hansch Approach to Drug Design. J. Med. Chem. 1977, 20, 463-469.
46. DeLano, W. L. The PyMOL Molecular Graphics System. DeLano Scientific: San Carlos, CA, 2002.
47. Huang, H.; Chopra, R.; Verdine, G. L.; Harrison, S. C. Structure of a Covalently Trapped Catalytic Complex of HIV-1 Reverse Transcriptase: Implications for Drug Resistance. Science 1998, 282, 1669-1675.
48. Jacobo-Molina, A.; Clark, A. D. Jr.; Williams, R. L.; Nanni, R. G.; Clark, P.; Ferris, A. L.; Hughes, S. H.; Arnold, E. Crystals of a ternary Complex of Human Immunodeficiency Virus Type 1 Reverse Transcriptase With a Monoclonal Antibody Fab Fragment and Double-Stranded DNA Diffract X-rays to 3.5-Å Resolution. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 10895-10899.
49. Ding, J.; Das, K.; Hsiou, Y.; Sarafianos, S. G.; Clark, A. D. Jr.; Jacobo-Molina, A.; Tantillo, C.; Hughes, S. H.; Arnold, E. Structure and Functional Implications of the Polymerase Active Site Region in a Complex of HIV-1 RT with a Double-Stranded DNA Template-Primer and an Antibody Fab Fragment at 2.8 Å Resolution. J. Mol. Biol. 1998, 284, 1095-1111.
50. Love, R. A.; Maegly, K. A.; Yu, X.; Ferre, R. A.; Lingardo, L. K.; Diehl, W.; Parge, H. E.; Dragovich, P. S.; Fuhrman, S. A. The Crystal Structure of the RNA-Dependent RNA Polymerase from Human Rhinovirus: A Dual Function Target for Common Cold Antiviral Therapy. Structure 2004, 12, 1533-1544.
51. Biswal, B. K.; Cherney, M. M.; Wang, M.; Chan, L.; Yannopoulos, C. G.; Bilimoria, D.; Nicolas, O.; Bedard, J.; James, M. N. Crystal Structures of the RNA-Dependent RNA Polymerase Genotype 2a of Hepatitis C Virus Reveal Two Conformations and Suggest Mechanisms of Inhibition by Non-Nucleoside Inhibitors. J. Biol. Chem. 2005, 280, 18202-18210.
52. Several compounds have been reported in clinical trials which have been shown to have a mechanism of action via covalent modification involving nucleophilic aromatic substitution by Cys239 of β-tubulin. For example see: Medina, J. C.; Houze, J.; Clark, D. L.; Schwender, S.; Beckmann, H.; Bei, S. Selective Irreversible Tubulin Binders with Efficacy Against Multi-Drug Resistant Tumor Cells. Abstracts of Papers, 222nd American Chemical Society National Meeting, Chicago, IL, Aug 26-30, 2001; ACS: Washington, DC.
53. Tanis, S. P.; Parker, T. T.; Colca, J. R.; Fisher, R. M.; Kletzein, R. F. Synthesis and Biological Activity of Metabolites of the Antidiabetic, Antihyperglycemic Agent Pioglitazone. J. Med. Chem. 1996, 39, 5053-5063.
54. Butcher, S. J.; Grimes, J. M.; Makeyev, E. V.; Bamford, D. H.; Stuart, D. I. A Mechanism for Initiating RNA-Dependent RNA Polymerization. Nature 2001, 470, 235-240.
55. Bressanelli, S.; Tomei, L.; Rey, F. A.; De Francesco, R. Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides. J. Virol. 2002, 76, 3482-3492.
56. Lee, G.; Piper, D. E.; Wang, Z.; Anzola, J.; Powers, J.; Walker, N.; Li, Y. Novel Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerases. J. Mol. Biol., in press.
57. Love, R. A.; Parge, H. E.; Yu, X.; Hickey, M. J.; Diehl, W. Gao, J.; Wriggers, H.; Ekker, A.; Wang, L.; Thomson, J. A.; Dragovich, P. S.; Fuhrman, S. A. Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5b RNA Polymerase Enzyme. J. Virol. 2003, 77, 7575-7581.
58. Tomei, L.; Altamura, S.; Bartholomew, L.; Biroccio, A.; Ceccacci, A.; Pacini, L.; Narjes, F.; Gennari, N.; Bisbocci, M.; Incitti, I.; Orsatti, L.; Harper, S.; Stansfield, I.; Rowley, M.; De Francesco, R.; Migliaccio, G. Mechanism of Action and Antiviral Activity of Benzimidazole-Based Allosteric Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase. J. Virol. 2003, 77, 13225-13231.
59. Pfefferkorn, J. A., Greene, M. L.; Nugent, R. A.; Gross, R. J.; Mitchell, M. A.; Finzel, B. C.; Harris, M. S.; Wells, P. A.; Shelly, J. A.; Anstadt, R. A.; Kilkuskie, R. E.; Kopta, L. A.; Schwende, F. J. Inhibitors of HCV NS5b Polymerase. Part 1: Evaluation of the Southern Region of (2Z)-2-(benzoylamino)- 3-(5-phenyl-2-furyl)-acrylic acid. Bioorg. Med. Chem. Lett. 2005, 15, 2481-2486.
60. Pfefferkorn, J. A.; Nugent, R.; Gross, R. J.; Greene, M.; Mitchell, M. A.; Reding, M. T.; Funk, L. A.; Anderson, R.; Wells, P. A.; Shelly, J. A.; Anstadt, R.; Finzel, B. C.; Harris, M. S.; Kilkuskie, R. E.; Kopta, L. A.; Schwende, F. J. Inhibitors of HCV NS5b Polymerase. Part 2: Evaluation of the Northern Region of (2Z)-2-benzoylamino-3-(4-phenoxy-phenyl)acrylic acid. Bioorg. Med. Chem. Lett. 2005, 75, 2812-2818.
61. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307-326.
62. Kissinger, C. R.; Gehlhaar, D. K.; Fogel, D. B. Rapid Automated Molecular Replacement by Evolutionary Search. Acta Crystallogr. D Biol. Crystallogr. 1999, 55 (Pt 2), 484-491.
63. Herman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
64. Brunger, A. T. X-PLOR version 3.1. A System for X-ray Crystallography and NMR; Yale University Press: New Haven, 1993.